Analysts Set Expectations for Dianthus Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:DNTH)

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Dianthus Therapeutics in a research note issued to investors on Thursday, June 27th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($2.54) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.12) per share.

A number of other equities research analysts also recently commented on DNTH. Raymond James lifted their target price on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research report on Thursday, April 18th. Jefferies Financial Group lifted their target price on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Wedbush lifted their target price on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, HC Wainwright assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, May 16th. They set a “buy” rating and a $40.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $42.83.

Dianthus Therapeutics Stock Up 5.2 %

NASDAQ:DNTH opened at $24.92 on Friday. Dianthus Therapeutics has a 12 month low of $6.58 and a 12 month high of $33.77. The company has a 50 day simple moving average of $23.71 and a two-hundred day simple moving average of $21.34.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, May 9th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The business had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.48 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC purchased a new position in shares of Dianthus Therapeutics during the 4th quarter valued at $25,000. Citigroup Inc. purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at $53,000. Acadian Asset Management LLC purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at $303,000. Virtu Financial LLC purchased a new position in shares of Dianthus Therapeutics during the 1st quarter valued at $390,000. Finally, Laurion Capital Management LP purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at $497,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.